Cargando…
A pancreas tumor derived organoid study: from drug screen to precision medicine
Pancreatic ductal adenocarcinoma (PDAC) one of the deadliest malignant tumor. Despite considerable progress in pancreatic cancer treatment in the past 10 years, PDAC mortality has shown no appreciable change, and systemic therapies for PDAC generally lack efficacy. Thus, developing biomarkers for tr...
Autores principales: | Yao, Jia, Yang, Man, Atteh, Lawrence, Liu, Pinyan, Mao, Yongcui, Meng, Wenbo, Li, Xun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314636/ https://www.ncbi.nlm.nih.gov/pubmed/34315500 http://dx.doi.org/10.1186/s12935-021-02044-1 |
Ejemplares similares
-
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank
por: Zhou, Zilong, et al.
Publicado: (2021) -
Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
por: Liu, Pinyan, et al.
Publicado: (2022) -
Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils
por: Xie, Ye, et al.
Publicado: (2023) -
Cell Therapy for Androgenetic Alopecia: Elixir or Trick?
por: Mao, Yongcui, et al.
Publicado: (2023) -
Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine
por: Spagnol, Giulia, et al.
Publicado: (2023)